Isomorphic Labs in Fundraising Discussions at $40–50 Billion Valuation

Isomorphic Labs/Drug design engine and pipeline

Isomorphic Labs, the AI drug-discovery spinout from Alphabet and DeepMind, is in early discussions to raise new funding at a valuation of at least $40 billion, potentially climbing to $50 billion, Bloomberg reported on October 8, 2026. The talks are preliminary and no deal has closed. The higher valuation represents significant growth just months after the company's May 2026 Series B round, which raised $2.1 billion. Isomorphic expects to dose its first clinical trial patients by the end of 2026 after operating for years without releasing clinical data.

• Isomorphic is in preliminary funding discussions at a $40–50 billion valuation, representing major growth since May 2026.
• The May 2026 Series B raised $2.1 billion, led by Thrive Capital and including Google Ventures, Alphabet, and new investors MGX, Temasek and CapitalG.
• Alphabet remains the majority shareholder and continues to support the company through Google Ventures.
• The company plans to dose its first clinical trial patients by the end of 2026, signaling progress toward human testing.
• Isomorphic uses AI to predict protein structures and design novel drugs, a capability that preclinical testing suggests has commercial potential.